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Abstract
Background: We recently showed that enzymes of the TET family convert 5-mC to 5-hydroxymethylcytosine (5-hmC) in
DNA. 5-hmC is present at high levels in embryonic stem cells and Purkinje neurons. The methylation status of cytosines is
typically assessed by reaction with sodium bisulfite followed by PCR amplification. Reaction with sodium bisulfite promotes
cytosine deamination, whereas 5-methylcytosine (5-mC) reacts poorly with bisulfite and is resistant to deamination. Since 5-
hmC reacts with bisulfite to yield cytosine 5-methylenesulfonate (CMS), we asked how DNA containing 5-hmC behaves in
bisulfite sequencing.
Methodology/Principal Findings: We used synthetic oligonucleotides with different distributions of cytosine as templates
for generation of DNAs containing C, 5-mC and 5-hmC. The resulting DNAs were subjected in parallel to bisulfite treatment,
followed by exposure to conditions promoting cytosine deamination. The extent of conversion of 5-hmC to CMS was
estimated to be 99.7%. Sequencing of PCR products showed that neither 5-mC nor 5-hmC undergo C-to-T transitions after
bisulfite treatment, confirming that these two modified cytosine species are indistinguishable by the bisulfite technique.
DNA in which CMS constituted a large fraction of all bases (28/201) was much less efficiently amplified than DNA in which
those bases were 5-mC or uracil (the latter produced by cytosine deamination). Using a series of primer extension
experiments, we traced the inefficient amplification of CMS-containing DNA to stalling of Taq polymerase at sites of CMS
modification, especially when two CMS bases were either adjacent to one another or separated by 1–2 nucleotides.
Conclusions: We have confirmed that the widely used bisulfite sequencing technique does not distinguish between 5-mC
and 5-hmC. Moreover, we show that CMS, the product of bisulfite conversion of 5-hmC, tends to stall DNA polymerases
during PCR, suggesting that densely hydroxymethylated regions of DNA may be underrepresented in quantitative
methylation analyses.
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Introduction
DNA methylation and demethylation occur dynamically during
early embryogenesis and play a crucial role in mammalian
development [1–5]. Changes in DNA methylation status are
associated with X-inactivation, imprinting, and the development
of primordial germ cells [2–5]; moreover, DNA methylation is
highly aberrant in cancer [6–9]. There is also a correspondence
between DNA methylation status and gene expression: the
promoters of silenced genes tend to be heavily methylated whereas
the promoters of active genes tend to be hypomethylated [3–5]. 5-
methyl cytosine (5-mC), the primary methylated base in DNA,
constitutes only ,1% of all DNA bases [2–5]. In somatic cells, 5-
mC is found almost exclusively in the context of paired
symmetrical methylation of the dinucleotide CpG [10,11] whereas
in embryonic stem (ES) cells, a substantial amount of 5-mC is also
observed in non-CpG contexts [12,13]. The majority of
methylated CpGs are located in repetitive DNA elements,
suggesting that cytosine methylation evolved as a defense against
transposons and other parasitic elements in DNA [5].
We and others have shown that the modified base, 5-
hydroxymethylcytosine (5-hmC), is present in mammalian
DNA; specifically, 5-hmC constitutes ,5% of all cytosine species
present at CpGs in MspI and Taq
aI sites in ES cell DNA, and
,20% of all cytosine species present at CpG’s in cerebellar
Purkinje cell DNA [14,15]. Since ES cells are highly proliferative
while Purkinje cells are post-mitotic, the biological functions of
5-hmC may differ depending on cell type. There are several
possible scenarios, not mutually exclusive. (i) Conversion of 5-
mC to 5-hmC could result in the displacement of 5-methylcyt-
PLoS ONE | www.plosone.org 1 January 2010 | Volume 5 | Issue 1 | e8888osine-binding proteins (MBPs) from methylated DNA; indeed at
least one MBP, MeCP2, does not bind DNA containing 5-hmC
[16] ; (ii) 5-hmC may promote DNA demethylation. Replace-
ment of 5-mC with 5-hmC may interfere with maintenance
methylation catalysed by DNMT1 during cell division [17],
resulting in ’’passive‘‘ DNA demethylation; alternatively, 5-hmC
may be recognized as an aberrant base by DNA repair
mechanisms that replace 5-hmC with cytosine, in a process
equivalent to ’’active‘‘ (replication-independent) demethylation;
(iii) 5-hmC may be recognized by dedicated binding proteins
that recruit specialized chromatin-modifying partners, thus
altering chromatin structure and DNA methylation status.
The TET proteins TET1, TET2 and TET3 are 2-oxogluta-
rate (2OG)- and Fe(II)-dependent oxygenases that catalyse the
conversion of 5-mC to 5-hmC in DNA [14]. TET1 and TET2
are both implicated in human leukemia, again arguing for the
physiological importance of 5-hmC. TET1 is an MLL fusion
partner and thus a likely oncogene: t(10;11)(q22;q23) transloca-
tions which fuse the N-terminal region of the histone-3 lysine-4
(H3K4) methyltransferase MLL with the catalytic domain of
TET1 have been found in several cases of acute myeloid and
lymphocytic leukemias (AML, ALL) [18–21]. Conversely, a
tumour suppressor function seems likely for TET2, based on
many reports of homozygous null mutations and chromosomal
deletions involving the TET2 locus in myelodysplastic syn-
dromes (MDS), myeloproliferative disorders (MPD) and frank
myeloid malignancies ([22–27] ; reviewed in [28,29]). 5-hmC
may also be generated by DNMT1-mediated oxidation of
cytosine with formaldehyde, although this has yet to be
demonstrated to occur under physiologically relevant conditions
[30] .
Taken together, these studies indicate that 5-hmC may have
important roles distinct from 5-mC. It is thus critical to understand
how 5-hmC behaves in techniques geared at mapping 5-mC. The
genomic location of 5-mC has been mapped in several ways. (i)
The 5-mC-binding domains of MBPs such as MeCP2, as well as
antibodies against 5-mC, have been used to precipitate methylated
DNA [31–36]. These reagents will not precipitate 5-hmC, as
neither the commonly used 5-mC antibody nor the MeCP2 MBD
domain bind 5-hmC effectively [14,16]. (ii) Methylation-sensitive
enzymes such as HpaII or McrBC do not reliably distinguish 5-
mC and 5-hmC [37,38]. (iii) For mapping 5-mC at single-base
resolution, either at specific loci or at the genome-wide level, the
most widely-used method is treatment with sodium bisulfite
followed by PCR amplification and sequencing [32,39,40]. The
bisulfite technique relies on the fact that reaction with sodium
bisulfite promotes deamination of unmethylated C to yield U,
which is read as T after PCR amplification (Figure 1A), whereas
5-mC reacts poorly with bisulfite and therefore is deaminated
much more slowly than C (Figure 1B). As a result, unmethylated
C is read as T in subsequent PCR reactions, whereas 5-mC is read
as C [39,40].
In this study, we examined the behaviour of 5-hmC-containing
DNA in bisulfite analysis. Sodium bisulfite reacts with 5-hmC to
yield a distinct adduct, cytosine 5-methylenesulfonate (CMS) [41]
(Figure 1C). We confirmed, as shown previously [41] , that 5-
hmC is not deaminated after bisulfite treatment, implying that a
proportion of genomic loci identified as methylated may actually
be hydroxymethylated. We also show that the CMS adduct tends
to stall DNA polymerases during PCR, especially if these modified
bases are adjacent to one another or spaced 1–2 nucleotides apart;
this result suggests that genomic regions containing closely-spaced
5-hmC could be missed or underrepresented in quantitative
methylation analyses.
Results
Sodium Bisulfite Treatment Does Not Distinguish
between 5-mC and 5-hmC
To test how 5-hmC affects bisulfite sequencing, we generated
DNA templates containing C, 5-mC or 5-hmC as their sole
cytosine species. To do this, we amplified a 201 bp oligonucle-
otide (Figure 2A) by PCR, using the nucleoside triphosphates
dATP, dGTP, dTTP and either dCTP or its 5-mC or 5-hmC
derivatives. The top strand of this oligonucleotide (201-bp)
contains 28 randomly distributed cytosines. Cytosine was
avoided in the primer-annealing region to ensure efficient
annealing after bisulfite treatment. The PCR products were
treated with bisulfite and exposed to conditions promoting
deamination and desulfonation.
We first measured the efficiency of C.T conversion after
bisulfite treatment (Figure 3). The 201 bp oligonucleotide, before
Figure 1. Reaction of sodium bisulfite with C, 5-mC and 5-hmC.
(A) Bisulfite-mediated deamination of cytosine. HSO3
2 reversibly and
quickly adds across the 5,6 double bond of cytosine, promoting
deamination at position 4 and conversion to 6-sulfonyluracil. 6-
sulfonyluracil is stable under neutral conditions, but is easily
desulfonated to uracil (U) at higher pH. (B) 5-methylcytosine is
deaminated to thymine by bisulfite conversion, but the rate is
approximately two orders of magnitude slower than that of cytosine.
(C) Bisulfite quickly converts 5-hydroxymethylcytosine to form cytosine-
5-methylenesulfonate (CMS). This adduct does not readily undergo
deamination [45].
doi:10.1371/journal.pone.0008888.g001
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PLoS ONE | www.plosone.org 2 January 2010 | Volume 5 | Issue 1 | e8888Figure 2. The bisulfite adduct of 5-hmC hinders PCR amplification. (A) Sequence of oligonucleotide containing multiple cytosines (used
in Figures 2B-D). The yellow highlighted sequences and the red asterisks indicate the sequences and cytosine (putative CMS) residues at which
DNA polymerases tended to stall when bisulfite-treated 5-hmC-containing DNA was used as template, whereas the grey highlighted sequences
and black asterisks indicate the sequences and cytosine (putative CMS) residues that cause weak or no stalling by the DNA polymerases (see
Figure 2D). Cytosines in the first 106 bases of the oligonucleotide are difficult to distinguish via Sanger sequencing and thus are not annotated
with regard to stalling. The underlined sequences correspond to the forward and reverse PCR primers used for PCR amplification. (B) Real-time
PCR amplification curve of an oligonucleotide containing C, 5-mC or 5-hmC before and after bisulfitet r e a t m e n t .T h es e q u e n c eo ft h e
oligonucleotide is shown in Figure 2A. The small lag observed for the bisulfite-treated cytosine oligonucleotide is due in part to the fact that
after conversion of cytosine to uracil, this oligonucleotide can only be amplified from one of the two strands. (C) Quantification of Ct value from
experiments performed as in Figure 2B. The mean and standard deviation of three experiments is shown. (D) Primer extension assays for DNA
containing different cytosine species, shown beside a Sanger sequencing ladder. Ladders of incomplete extension products were only observed
in the 5-hmC-containing DNA after bisulfite treatment, at positions corresponding to G in the Sanger sequencing ladder (left lanes). Red
asterisks: positions with the most significant stalling; black asterisks: positions with weak stalling or no stalling. The corresponding sequences
are indicated on the left (please compare with Figure 2A). The extension reaction performed with bisulfite-treated 5-hmC-containing DNA
yielded less full-length product (arrow).
doi:10.1371/journal.pone.0008888.g002
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respectively), was digested with nuclease P1 and subjected to LC-
MS analysis. Observed m/z values and corresponding dNMP
structure are indicated (mass accuracy is within 0.002 Da). After
bisulfite treatment, hm-dCMP (Figure 3A, upper panel, peak at
336.0606 Da) is not detectable because it is converted to ms-
dCMP (lower panel, peak at 400.0277 Da). Similarly, the cytosines
in the primers (upper panel, peak at 306.0526 Da) undergo
conversion to uracil, resulting in the peak corresponding to dUMP
(lower panel, peak at 307.0415 Da).
Figure 3. LC-MS analysis of conversion efficiency of 5-hmC to CMS. (A) MS analysis of the nuclease P1 digestion products of the
oligonucleotides used in Figure 2A, before (upper panel) and after (lower panel) bisulfite treatment. (B) To determine the conversion efficiency of 5-
hmC to CMS in the oligonucleotide shown in Figure 2A, a standard curve was used to determine the unknown quantity of hmdCMP in the sample
before and after treatment with sodium bisulfite (see text for details). The absolute value of the intercept of the best-fit line with the X-axis gives the
concentration of hmdCMP remaining in the sample after bisulfite treatment as 4.69 nM. Given that the hmdCMP concentration before bisulfite
treatment was 1.5 mM, this corresponds to a conversion efficiency as high as 99.7%.
doi:10.1371/journal.pone.0008888.g003
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generated (Figure 3B). Seven aliquots were taken from the
reaction mixture after treatment with sodium bisulfite, and a
known amount of authentic hmdCMP was added to each aliquot,
corresponding to a final concentration of 0, 1 nM, 5 nM, 10 nM,
20 nM, 50 nM, or 100 nM added hmdCMP. Each of the resulting
samples was analyzed by LC/MS: 10 mL of each sample was
injected, and duplicate LC/MS analyses were performed for each
sample. The average ion abundance of [M–H] m/z=336.06 for
each sample was plotted as a linear function of the concentration of
authentic hmdCMP added. The absolute value of the intercept of
the best-fit line with the X-axis provides the concentration of
hmdCMP remaining in the original sample after bisulfite treatment
(calculated to be 4.69 nM). Since the hmdCMP concentration
before bisulfite treatment was 1.5 mM, this level of remaining
hmdCMP corresponds to a conversion efficiency of 99.7%.
We then sequenced the amplified DNA oligonucleotides before
and after bisulfite treatment. Sequencing confirmed that all
cytosines in the oligonucleotide were converted to thymines after
bisulfite treatment; a representative sequence is shown (Figure 4A,
lower panel). In contrast, bisulfite-treated 5-hmC did not undergo
C-.T transitions, as expected from its chemical and base pairing
properties [41] (Figure 4A, upper panels). Since 5-mC also does
not undergo conversion under these conditions [41], our results
indicate that the widely-used bisulfite sequencing technique fails to
distinguish between 5-mC and 5-hmC. To test whether commer-
cially available anti-5mC antibodies recognize 5-hmC, equivalent
amounts of 5-mC- or 5-hmC- containing oligonucleotide were
spotted on a nitrocellulose membrane (Figure 4B), incubated
with anti 5-mC antibody, and visualized via chemiluminescence.
5-hmC was not recognized by the anti-5mC antibody (Figure 4B).
This indicates that sites of hydroxymethylation would likely appear
methylated by bisulfite sequencing but unmethylated by detection
techniques that rely on antibody [14,16].
The Bisulfite Adduct of 5-hmC Hinders PCR Amplification
We next asked if the presence of the bulky CMS adduct might
hinder PCR amplification. The PCR-amplified oligonucleotides
Figure 4. 5-hmC did not undergo C-.T transitions after bisulfite treatment and 5-mC antibody cannot recognize 5-hmC in DNA. (A)
Shown are sequencing traces of 5-hmC-containing oligonucleotide (Figure 2A) before and after bisulfite treatment (top and middle panels). The
control C-containing oligonucleotide shows complete conversion of all C’s in the top strand (highlighted sequences) to T’s (lower panel). (B) Dot-blot
assay of monoclonal anti-5-mC antibody detection of oligonucleotide (Figure 2A) containing 5-mC or 5-hmC (Figure 2A). Recognition on DNA by
the anti-5-mC antibody is shown in the top panel, loading control is shown by the methylene blue stain in the bottom panel. The anti-5-mC antibody
only recognizes the 5-mC oligonucleotide but not the 5-hmC oligonucleotide.
doi:10.1371/journal.pone.0008888.g004
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and amplified with the primers shown in Figure 2A. The
amplification efficiencies were measured by real-time PCR. Under
these conditions, 5-hmC-containing DNA was very inefficiently
amplified compared to C- and 5-mC-containing DNA
(Figures 2B, C).
To determine where the block in PCR amplification occurred,
we performed primer extension assays using two commercial
sources of Taq DNA polymerase. A ladder of incomplete
extension products was seen only with bisulfite-treated, 5-hmC-
containing DNA (Figure 2D). The most significant stalling
(marked with red asterisks in Figures 2A, D) occurred at
positions across from a CTC sequence close to the end of the
reverse primer, and a CCGC sequence and several CC sequences
further away. Cytosine residues where stalling was weak or did not
occur are marked with black asterisks (Figures 2A, D). The
results suggest that CMS stalls but does not completely block Taq
polymerase, and that the stalling is particularly pronounced when
two CMS nucleotides are adjacent to one other or separated by a
single nucleotide as in the CTC sequence.
The Bisulfite Adduct of 5-hmC Stalls Taq Polymerase at
CpG Dinucleotides
In mammalian DNA, 5-mC (and presumably its hydroxylated
derivative, 5-hmC) are found almost exclusively in the context of
the dinucleotide CpG [10,11]; however, DNA from embryonic
stem cells contains 5-mC in non-CpG contexts [12,13]. To
evaluate the degree to which CMS would stall Taq polymerase in
this physiological context, we synthesized a set of 158 bp
oligonucleotides in which the top strand contained a variable
sequence that was one of the following: CGAT, CCAT, CGCG,
or CCGG (indicated by XXXX in Figure 5A). After bisulfite
treatment, the most significant stalling was observed at the
tandem CC sequences in the CC and CCGG oligonucleotides
(red asterisks in Figure 5B, lanes 6, 8). Bisulfite-dependent
stalling was also observed to a lesser degree at the same position
in the CG and CGCG oligonucleotides (red asterisks in
Figure 5B, lanes 2, 4).
Consistent with these observations, the CG and CGCG
oligonucleotides were efficiently amplified after bisulfite treatment,
whereas oligonucleotides containing CC sequences showed a
perceptible decrease in amplification efficiency (Figure 5C). Note
that the PCR amplification is performed with standard nucleo-
tides, yielding PCR products that contain A, C, G and T but no
CMS. Therefore, the observed difference in Ct values between
bisulfite-treated and untreated CC and CCGG oligonucleotides
most likely arises from inefficient initial production of full-length
PCR products; once generated, full-length PCR products will be
amplified as efficiently as any other DNA.
To summarize, we have traced the inefficient amplification of
CMS-containing DNA to the fact that CMS residues tend to stall
Taq polymerases. The extent of stalling varies with DNA sequence
and with the polymerase used, but is perceptible in the context of a
single CMS-guanine dinucleotide and is pronounced in sequence
contexts where CMS residues are adjacent or within 1–2
nucleotides of one another.
Discussion
In summary, we have confirmed that 5-hmC does not undergo
C-to-T transitions after bisulfite treatment, and thus cannot be
distinguished from 5-mC by the bisulfite technique. In addition,
we find that primer extension reactions conducted with bisulfite-
treated DNA terminate disproportionately at sites of hydroxy-
methylation, bringing up the distinct possibility that bisulfite-based
analyses of DNA methylation status could miss or underestimate
the occurrence of DNA regions with dense hydroxymethylation.
We initiated these studies in light of the recent discovery, by us
and others, that 5-hmC is a bona fide constituent of mammalian
DNA, especially in ES cells and Purkinje neurons [14,15]; and our
own finding that the enzymes that catalyse the conversion of 5-mC
to 5-hmC in DNA belong to the TET protein family [14]. There
has been a recent proliferation of studies in which the DNA
methylation status of plant and mammalian genomes has been
mapped, most recently using whole-genome bisulfite sequencing
alone [13], but more often through bisulfite sequencing of DNA
enriched by MeDIP (immunoprecipitation of methylated DNA
using either specific antibodies to 5-mC or the methyl-CpG-
binding domains of MBPs such as MeCP2) [31–36] . Specifically,
genome-wide maps of DNA methylation were recently achieved
for Arabidopsis thaliana and for human ES cells by generating
bisulphite sequencing libraries compatible with next-generation
deep sequencing (BiS-seq) [13,32].
Many of the mammalian mapping studies have been performed
in embryonic stem cells, which are known to contain 5-hmC [14],
or in cancer cell lines, in which DNA methylation is known to be
aberrant [6–9]. We therefore tackled the question of how 5-hmC
might be interpreted in the traditional bisulfite-based methods of
DNA methylation analysis. We used two synthetic oligonucleotides
with different distributions of cytosine species to compare the
behaviour of C, 5-mC and 5-hmC in the bisulfite technique. The
first of these oligonucleotides contained C, 5-mC or 5-hmC as
their sole cytosine species in the top strand in both CpG and non-
CpG contexts (28 cytosines/201 bases, or 14%). We first
confirmed by mass spectrometry that .99% of 5-hmC was
converted to the expected CMS adduct [41] upon reaction with
bisulfite (Figure 1), and that CMS, like 5-mC, was resistant to
deamination and therefore was read as C upon PCR amplification
(Figure 2). We also found, however, that this oligonucleotide was
very poorly amplified after PCR (Figure 2A), suggesting that the
bulky CMS adduct generated by the reaction of bisulfite with 5-
hmC (Figure 1) interfered with PCR amplification. We traced the
problem to the fact that two different Taq polymerases, both
constituents of commercial bisulfite kits, were stalled by CMS,
especially in regions of dense hydroxymethylation where two CMS
residues were adjacent or were separated by only one or two
nucleotides.
Since much cytosine methylation in mammalian cells occurs in
the context of CpG dinucleotides [11–13], we designed a second
oligonucleotide that contained one CpG and an additional
sequence of four bases that included CC, CG, CCGG or CGCG.
Again, stalling was prominent at tandem CC sequences, which
would be converted to tandem CMS sequences after bisulfite
treatment (Figure 5). However, there was also clear bisulfite-
dependent stalling at the CpG sequences in the CG and CGCG
oligonucleotides. These findings imply that bisulfite sequencing
data should be interpreted with caution, since loci containing dense
regions of hydroxymethylated DNA might be incorrectly assumed
to contain methylated CpGs, and might also be underrepresented
in quantitative analyses of DNA methylation status.
Notably, genome-wide analyses of cytosine methylation in ES
cells has shown that ,25% of all 5-mC is in a non-CpG context;
two C’s that are immediately adjacent can both be methylated
[13]. We have shown that the CC sequence context is particularly
liable to stall Taq polymerases after 5-hmC.CMS conversion
(Figures 2D, 5B), therefore DNA regions that contain tandem 5-
hmC’s might be under-represented through inefficient PCR
amplification after bisulfite treatment. At present it is difficult to
5-hmC in Bisulfite Sequencing
PLoS ONE | www.plosone.org 6 January 2010 | Volume 5 | Issue 1 | e8888Figure 5. The bisulfite adduct of 5-hmC stalls Taq polymerase at CpG dinucleotides. (A) Sequences of a set of five 158 bp oligonucleotides
used in this assay. At the position marked XXXX (red font with yellow highlight), the CG oligonucleotide contains the sequence CGAT, the CGCG
oligonucleotide contains two tandem CGs, and the CC and CCGG oligonucleotides contain CCAT and CCGG sequences respectively. The underlined
sequences correspond to the forward and reverse PCR primers used for PCR amplification. (B) Primer extension assays of oligonucleotides shown in
Figure 5A. The bands corresponding to stalled PCR reactions (red asterisks, see XXXX in Figure 5A) were most prominent in 5-hmC-containing CC
and CCGG oligonucleotides after bisulfite treatment, and were observed, though less obvious, in the CG and CGCG oligonucleotides. Full length
product is indicated by an arrow. Right lanes, the Sanger sequencing was performed using the CCGG oligonucleotide as a template. (C) Quantification
of Ct value of real-time PCR from experiments performed on the substrates used in Figure 5A. The mean and standard deviation of three
experiments is shown.
doi:10.1371/journal.pone.0008888.g005
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hydroxymethylated loci have been identified, and immunoprecip-
itation strategies to identify endogenous 5-hmC-containing loci in
ES or Purkinje cell DNA have not yet been developed.
It may be possible in future to exploit our finding that primer
extension reactions conducted with bisulfite-treated DNA termi-
nate disproportionately at sites of hydroxymethylation. Primer
extensions with appropriate polymerases could be performed,
possibly under suboptimal extension conditions, and combined
with ligation-mediated PCR to establish the genomic location of 5-
hmC at single-base (‘‘horizontal‘‘ [39]) resolution.
It is unclear how CMS inhibits PCR. Rein et al. proposed that
the bulky CMS adduct would block DNA polymerase by analogy
to oxidative pyrimidine adducts such as thymine glycol [42,43] or
6-sulfonyluracil [44]. However, CMS retains aromaticity, whereas
it has been demonstrated that polymerases are disrupted by
thymine glycol’s loss of aromaticity and consequent adoption of a
six-membered ring chair geometry [12]. Whatever the mecha-
nism, the observation that 5-hmC can stall Taq polymerase after
bisulfite reactions has important ramifications for our interpreta-
tion of previous DNA methylation analyses as discussed above.
Materials and Methods
Design of Minigenes for Generation of DNA Templates
Containing C, 5-mC or 5-hmC
Minigenes used as templates to amplify C, 5-mC or 5-hmC
containing oligonucleotides (Figure 2 and Figure 5) were
synthesized by Integrated DNA Technologies. DNA containing
C, 5-mC or 5-hmC was amplified by PCR using 0.2 mM
nucleoside triphosphates dATP, dGTP, dTTP with dCTP or its
derivatives mdCTP (GE Healthcare) or hmdCTP (Bioline). PCR
products were run on a 2% agarose gel to confirm correct length
and further purified by a gel extraction kit (Qiagen).
Bisulfite Treatment of Oligonucleotides
Bisulfite treatment and recovery of samples were carried out
with the EpiTect Bisulfite kit (QIAGEN) by following the
manufacturer’s instructions. Briefly, 2 mg DNA in 20 mL volume
was used for each reaction and mixed with 85 mL bisulfite mix and
35 mL DNA protect buffer. Bisulfite conversion was performed on
a thermocycler as follows: 99uC for 5 min, 60uC for 25 min, 99uC
for 5 min, 60uC for 85 min, 99uC for 5 min, 60uC for 175 min
and 20uC indefinitely. The bisulfite-treated DNA was recovered
by EpiTect spin column and subsequently sequenced to confirm
the efficiency of bisulfite conversion.
Liquid Chromatography/Mass Spectrometry Analysis
The bisulfite-treated oligonucleotide shown in Figure 2 was
precipitated with ethanol, digested by nuclease P1, lyophilized,
and redissolved in water for liquid chromatography/mass
spectrometry (LC/MS) analysis using an Acquity UPLC/Q-
TOF Premier electrospray LC/ESI-MS system (Waters Corp.,
Milford, MA). Liquid chromatography was performed with a
Waters HSS C18 column (1.0 mm i.d.650 mm, 1.8-um particles)
using a linear gradient of 0% to 100% methanol in 0.1% aqueous
ammonium formate, pH 6.0. The flow rate was 0.03 mL/min and
the eluant was directly injected into the mass spectrometer. The
data were analyzed using the Masslynx 4.1 software package
(Waters).
RealTime PCR of Oligonucleotides
RealTime PCR was performed on the StepONE plus real-time
PCR system (Applied Biosystems) by using the FastStart Universal
SYBR Green Master kit (Roche). 0.1 mg DNA template and
0.15 mM primers were used in each reaction in a final volume of
20 mL. The amplification reaction program was set as: 95uC for
10 min, 40 cycles of 95uC for 15 sec, 60uC for 1 min, and a melt
curve analysis step at the end. Data were analyzed by StepONE
plus real-time PCR software.
Primer Extension Assay
Reverse primers (50 ng) were end labeled with T4 polynucle-
otide kinase (T4 PNK) (NEB) and 10 mCi of [c-
32P]-ATP
(PerkinElmer) for 1 hr at 37uC, and then purified by Illustra
MicroSpin G-25 column (GE Healthcare). For the primer
extension, 2 ng template and 4 pmol c
32-P-labeled primers were
used in a final volume of 20 mL. PCR reactions were set up
according to the manufacturer’s instructions using two commercial
sources of Taq DNA polymerase (Roche and Sigma). For Roche
Taq DNA polymerase, PCR conditions were: 95uC for 10 min, 30
cycles of 95uC for 15 sec, 60uC for 1 min. For Sigma TaqRED
polymerase, PCR conditions were: 30 cycles of 94uC for 1 min,
55uC for 2 min and 72uC for 1 min. The primer extension
products were mixed with 2X gel loading buffer II (Ambion),
denatured at 95uC for 15 min and loaded on to a 12% denaturing
polyacrylamide gel (7 M urea). Sanger sequencing was performed
using Thermo Sequenase Dye Primer Manual Cycle Sequencing
kit (USB). 2 ng template and 1 pmol [c
32-P]-labeled primer were
used for Sanger sequencing. The results were visualized by
autoradiography.
Dot-Blot Assay
5-mC and 5-hmC oligonucleotides were generated as described
above. 2 mg of DNA was denatured in 0.4 M NaOH, 10 mM
EDTA at 95uC for 10 min, and then neutralized by adding an
equal volume of cold 2 M ammonium acetate (pH 7.0). Next, 2-
fold dilutions of denatured DNA samples were spotted on a
nitrocellulose membrane in an assembled Bio-Dot apparatus (Bio-
Rad). Vacuum was subsequently applied to filter through DNA
samples. The blotted membrane was washed with 2x SSC buffer,
air-dried and vacuum-baked at 80uC for 2 hrs. The membrane
was then blocked with 5% non-fat milk and incubated with
monoclonal 5-mC antibody (1:1000) (Calbiochem). Binding of an
HRP-conjugated secondary antibody (1:12000) was visualized by
enhanced chemiluminescence. To ensure equal spotting of total
DNA on the membrane, the same blot was then stained with
0.02% methylene blue in 0.3 M sodium acetate (pH 5.2).
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